Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nuwellis ( (NUWE) ) has shared an announcement.
On August 21, 2025, Nuwellis, Inc. announced that it has received FDA 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). This clearance may enhance the company’s product offerings and potentially improve its market position in the medical device industry.
The most recent analyst rating on (NUWE) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’ overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. While there are positive strategic initiatives and corporate events, the immediate financial challenges and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Average Trading Volume: 1,058,436
Technical Sentiment Signal: Sell
Current Market Cap: $5.38M
See more insights into NUWE stock on TipRanks’ Stock Analysis page.